What is Gamida Cell?
Founded in 1998 and headquartered in Boston, MA, Gamida Cell is dedicated to advancing innovative cell therapies. The company's pipeline targets severe hematological conditions, aiming to provide curative solutions where current treatments fall short. Its clinical-stage development signifies a critical phase of growth, moving therapies from research to potential market availability.
How much funding has Gamida Cell raised?
Gamida Cell has raised a total of $100M across 2 funding rounds:
Debt
$75M
Debt
$25M
Debt (2021): $75M with participation from Highbridge Capital Management
Debt (2022): $25M led by Highbridge Capital Management
Key Investors in Gamida Cell
Highbridge Capital Management
Highbridge Capital Management is a global alternative investment firm based in New York, New York, known for its hedge fund strategy services and liquidity products. Their participation suggests a strategic financial backing for Gamida Cell's development.
What's next for Gamida Cell?
The recent major strategic investment in Gamida Cell signals a pivotal moment for the company's expansion and the advancement of its therapeutic candidates. This capital infusion is expected to accelerate clinical development programs, bolster manufacturing capabilities, and support regulatory submissions. The company's focus on addressing unmet needs in blood cancers and serious blood diseases positions it for significant future growth and potential market leadership.
See full Gamida Cell company page
